Novo Nordisk Buys Time With Nanexa Deal and US Job Cuts as Shares Stay Under Pressure
Article excerpt
Highlighted: the sentence this signal was extracted from
Novo Nordisk is betting that longer dosing intervals and a slimmer American cost base can offset the twin pressures of patent expirations and skeptical investors. The Danish drugmaker has moved on two fronts in quick succession: a licensing alliance worth up to EUR 1.165 billion with Swedish drug-delivery specialist Nanexa, and a workforce reduction at its US headquarters in Plainsboro, New Jersey. Announced on 24 September, the worldwide license and collaboration agreement hands Novo Nordisk access to Nanexa's PharmaShell delivery technology across as many as five development programs. The targets span obesity, type 2 diabetes and other cardiometabolic indications, with the goal of stretching administration intervals to a monthly or quarterly rhythm. Nanexa stands to collect up to EUR 1.165 billion in total, comprising EUR 615 million in upfront, development and milestone payments, plus royalties in the low single-digit percentage range. The deal is the clearest signal yet of how management intends to defend its franchise as investors question future pricing power and brace for key products to lose exclusivity. Longer-acting formulations are central to that effort, alongside a push into oral therapies. Roughly a week before the Nanexa announcement, Novo Nordisk secured exclusive rights to the oral candidate HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan. The...
Keep reading with a free account
The rest of this article, and every signal for Novo Nordisk, is in your free account.
